Physician profile
Ankur Jain
NPI 1306866207
$7,599.09
in general payments reported to CMS, 2019-2025
29 companies · $2,601 in 2025
The $2,601 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $870 · 2020: $414 · 2021: $275 · 2022: $1,028 · 2023: $673 · 2024: $1,738 · 2025: $2,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,843 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,842.82 |
| Education | $168.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,086.24 | 2023-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $1,056.34 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $603.48 | 2020-2024 | Entyvio, Gattex |
| Gilead Sciences, INC. | $564.63 | 2021-2025 | Livdelzi |
| Intercept Pharmaceuticals, INC. | $472.75 | 2019-2024 | |
| Pfizer INC. | $337.40 | 2019-2024 | |
| Eli Lilly and Company | $328.04 | 2025 | Trulicity |
| Madrigal Pharmaceuticals | $309.97 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $289.98 | 2022-2024 | |
| Allergan, INC. | $284.80 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $262.58 | 2020-2023 | Zeposia |
| Exact Sciences Corporation | $241.49 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ferring Pharmaceuticals INC. | $189.35 | 2019-2025 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $185.92 | 2024-2025 | Iqirvo |
| Orphalan INC | $174.23 | 2024 | Cuvrior |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $147.02 | 2023-2025 | Dupixent |
| Novo Nordisk INC | $140.97 | 2025 | Wegovy |
| Baxter Healthcare | $121.60 | 2024 | Renal - Acute |
| Boston Scientific Corporation | $108.53 | 2025 | Overstitch Endoscopic Suturing System |
| Abbott Laboratories | $103.47 | 2025 | Cardiomems |
| Celltrion USA INC. | $91.19 | 2025 | Vegzelma |
| Covidien LP | $87.42 | 2019 | |
| Janssen Scientific Affairs, LLC | $85.20 | 2025 | Tremfya |
| Micro-Tech Endoscopy USA, INC. | $84.64 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $59.21 | 2022-2023 | Dupixent |
| Medtronic, INC. | $49.91 | 2022 | |
| Novartis Pharmaceuticals Corporation | $48.50 | 2019 | |
| Celgene Corporation | $42.37 | 2022-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $41.86 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankur Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.